Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Recurrence of breast cancer in elderly women.

Serraino D, Berretta M, Tirelli U.

J Clin Oncol. 2014 Jan 10;32(2):161. doi: 10.1200/JCO.2013.52.9081. Epub 2013 Dec 9. No abstract available.

PMID:
24323029
2.

Reply to D. Serraino et al.

Partridge AH, Gelber S, Gelber R.

J Clin Oncol. 2014 Jan 10;32(2):161. doi: 10.1200/JCO.2013.53.2705. Epub 2013 Dec 9. No abstract available.

PMID:
24323031
3.

Breakthrough in breast cancer treatment. "Smart bullet" T-DM1 delivers a payload to cancer cells and avoids healthy ones.

[No authors listed]

Duke Med Health News. 2012 Aug;18(8):3. No abstract available.

PMID:
23029673
4.

Hormone receptor status affects locoregional control in HER2-positive breast cancer treated with trastuzumab.

Barton MK.

CA Cancer J Clin. 2012 Sep-Oct;62(5):281-2. doi: 10.3322/caac.21152. Epub 2012 Jul 30. No abstract available.

5.

Trastuzumab in the treatment of breast cancer.

Hortobagyi GN.

N Engl J Med. 2005 Oct 20;353(16):1734-6. No abstract available.

6.

Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer.

Oguz A, Keskin GS, Colak D, Altundag O, Akcali Z.

J Clin Oncol. 2016 Feb 20;34(6):639-40. doi: 10.1200/JCO.2015.63.8411. Epub 2015 Dec 7. No abstract available.

PMID:
26644534
7.

Cardiac toxicity monitoring for HER2-positive breast cancer patients undergoing trastuzumab therapy: are we doing enough?

Gujral DM, Lloyd G, Bhattacharyya S.

Clin Oncol (R Coll Radiol). 2013 Jul;25(7):446-7. doi: 10.1016/j.clon.2013.03.006. Epub 2013 Apr 11. No abstract available.

PMID:
23583229
8.

Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.

[No authors listed]

Prescrire Int. 2013 Feb;22(135):39. Review.

PMID:
23444499
9.

Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.

Cho WC, Roukos DH.

Expert Rev Anticancer Ther. 2013 Jan;13(1):5-8. doi: 10.1586/era.12.152. No abstract available.

PMID:
23259420
10.

Reply to A. Oguz et al.

O'Sullivan CC, Holmes E, Campbell C, Bradbury I, Zujewski JA, Gelber RD.

J Clin Oncol. 2016 Feb 20;34(6):640-1. doi: 10.1200/JCO.2015.65.1034. Epub 2015 Dec 7. No abstract available.

PMID:
26644531
11.

Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.

Ferretti G, Fabi A, Felici A, Papaldo P.

J Clin Oncol. 2010 Jul 10;28(20):e337; author reply e338-9. doi: 10.1200/JCO.2010.28.2525. Epub 2010 May 17. No abstract available.

PMID:
20479395
12.

Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial.

Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E, Winer EP, Gelber RD.

J Clin Oncol. 2013 Jul 20;31(21):2692-8. doi: 10.1200/JCO.2012.44.1956. Epub 2013 Jun 10.

PMID:
23752109
13.

Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors.

Tuma RS.

J Natl Cancer Inst. 2012 Jul 3;104(13):968-9. doi: 10.1093/jnci/djs307. Epub 2012 Jun 28. No abstract available.

PMID:
22745473
14.

HER2 status and benefit from adjuvant trastuzumab in breast cancer.

Paik S, Kim C, Wolmark N.

N Engl J Med. 2008 Mar 27;358(13):1409-11. doi: 10.1056/NEJMc0801440. No abstract available.

15.

[Herceptin monotherapy in HER2(+) recurrent breast carcinoma].

Eidtmann H.

Onkologie. 2002 Dec;25 Suppl 5:14-5. German. No abstract available.

PMID:
23573613
16.

Health care costs: how do we decide value? When do we decide? How do we particularize the decisions?

Theriault RL.

Oncologist. 2012;17(2):157-9. doi: 10.1634/theoncologist.2011-0371. Epub 2012 Feb 2. No abstract available.

17.

Translational cancer research in Europe.

Fricker J.

Mol Oncol. 2007 Jun;1(1):8-10. No abstract available.

18.

Trastuzumab: qui bono?

Krop IE, Burstein HJ.

J Natl Cancer Inst. 2013 Dec 4;105(23):1772-5. doi: 10.1093/jnci/djt336. Epub 2013 Nov 21. No abstract available.

PMID:
24262439
19.

Introduction. Herceptin: HER2 status--changing clinical practice.

Piccart M, Kaufmann M.

Eur J Cancer. 2001 Jan;37 Suppl 1:S1-2. No abstract available.

PMID:
11167084
20.

Ado-trastuzumab emtansine approved for advanced breast cancer.

Traynor K.

Am J Health Syst Pharm. 2013 Apr 1;70(7):562. doi: 10.2146/news130023. No abstract available. Erratum in: Am J Health Syst Pharm. 2013 May 15;70(10):840.

PMID:
23515502

Supplemental Content

Support Center